Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

Aarkstore.com lay before the public a new report through its very spacious collection of market research report :

Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

For some-more information, Great fully visit:

http://www.aarkstore.com/reports/Case-Study-HIV-Better-discriminating-pricing-strategies-are-needed-to-ensure-access-to-HIV-drugs-136225.html

   
Introduction

Although the majority of HIV drug developers already propound most of their antiretrovirals under discriminating pricing schemes for lower income countries, small in number can compete with the lower prices of available generics offered through donor-funded programs. Innovative ways fust be found that can balance widespread passage to newer HIV drugs while silent ensuring profits for pharmaceutical companies.

Features and benefits

* Discussion of differential pricing strategies for pharmaceuticals
* Review of discriminating pricing strategies for HIV antiretrovirals
* Analysis of driving forces rearward the need for better differential pricing strategies towards antiretrovirals
* Discussion of incentives that could boost differential pricing policies

Highlights

Although differential pricing strategies are inmost nature employed in some areas, several obstacles hold so far limited a more widespread utilization. Key difficulties embody the threat of parallel trade, extrinsic reference pricing, decreased buying power in humiliate income countries, and concerns that preferential prices are not passed in successi~ to consumers.
Generics have increasingly driven into disrepute the price for antiretrovirals in let down income markets, making it difficult ~ the sake of pharmaceutical companies and their branded products to stay based on competition despite using differential pricing strategies
An increasing penury for later-stage treatments and stricter inculcation of intellectual property (IP) rights invitation for improved strategies to enhance passage-way to newer antiretrovirals

Your key questions answered

* Understand wherefore many HIV markets in developing countries are dominated ~ dint of. generics despite differential pricing by innovative remedy developers.
* Learn how differential pricing be able to be a win-win strategy to advance access to drugs while retaining incentives with a view to pharmaceutical companies.
* Understand why better differential pricing strategies will be key in allowing fit to newer antiretrovirals.
     

Table of Contents :
Executive Summary
Strategic scoping and converging-point
key findings
Related reports
OVERVIEW
Catalyst
Summary
DIFFERENTIAL PRICING FOR PHARMACEUTICALS - AN INTRODUCTION
Key points
Introduction
Differential pricing be possible to be a strategy to boost entranceway to medicines while augmenting company profits
Differential pricing can be a tool to penetrate untapped markets
Despite TRIPs, generic descent continues to threaten profits of innovative remedy developers in lower income markets
Differential pricing policies be able to demonstrate corporate social responsibility
Several obstacles thwart the broad utilization of differential pricing toward medicines
Parallel trade is one of the the gross arguments against differential pricing
Reference pricing makes multitude companies reluctant to agree to preferential prices
Lower prices as antidote to medicines do not automatically lead to enhanced fit
So far, the utilization of discriminating pricing strategies remains limited
THE ROLE OF DIFFERENTIAL PRICING IN HIV THERAPY ACCESS
Key points